| Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor A Norden-Zfoni, J Desai, J Manola, P Beaudry, J Force, R Maki, ... Clinical Cancer Research 13 (9), 2643-2650, 2007 | 250 | 2007 |
| Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells … P Beaudry, J Force, GN Naumov, A Wang, CH Baker, A Ryan, S Soker, ... Clinical Cancer Research 11 (9), 3514-3522, 2005 | 208 | 2005 |
| The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in … OM Fayanju, Y Ren, SM Thomas, RA Greenup, JK Plichta, ... Annals of surgery 268 (4), 591-601, 2018 | 176 | 2018 |
| Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve I Celik, O Sürücü, C Dietz, JV Heymach, J Force, I Höschele, ... Cancer research 65 (23), 11044-11050, 2005 | 162 | 2005 |
| Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells G Schuch, JV Heymach, M Nomi, M Machluf, J Force, A Atala, JP Eder Jr, ... Cancer research 63 (23), 8345-8350, 2003 | 147 | 2003 |
| Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin GD Girnun, L Chen, J Silvaggi, R Drapkin, LR Chirieac, RF Padera, ... Clinical cancer research 14 (20), 6478-6486, 2008 | 102 | 2008 |
| Mechanisms of therapeutic antitumor monoclonal antibodies LC Tsao, J Force, ZC Hartman Cancer research 81 (18), 4641-4651, 2021 | 101 | 2021 |
| Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database CT Ong, BM Campbell, SM Thomas, RA Greenup, JK Plichta, ... Annals of surgical oncology 25, 2249-2260, 2018 | 98 | 2018 |
| Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non–small-cell lung cancer receiving sorafenib RJ Kelly, A Rajan, J Force, A Lopez-Chavez, C Keen, L Cao, Y Yu, ... Clinical cancer research 17 (5), 1190-1199, 2011 | 85 | 2011 |
| Checkpoint blockade strategies in the treatment of breast cancer: where we are and where we are heading J Force, JHS Leal, HL McArthur Current treatment options in oncology 20 (4), 35, 2019 | 57 | 2019 |
| First-line treatment of metastatic melanoma: role of nivolumab J Force, AKS Salama ImmunoTargets and therapy, 1-10, 2017 | 42 | 2017 |
| RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence CC Lin, NW Mabe, YT Lin, WH Yang, X Tang, L Hong, T Sun, J Force, ... Cell Death & Differentiation 27 (7), 2234-2247, 2020 | 41 | 2020 |
| Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and αPD-1 enable sustained antitumor responses against established HER2 breast cancer EJ Crosby, CR Acharya, AF Haddad, CA Rabiola, G Lei, JP Wei, XY Yang, ... Clinical Cancer Research 26 (17), 4670-4681, 2020 | 38 | 2020 |
| Biomarkers of immune checkpoint blockade response in triple-negative breast cancer J Isaacs, C Anders, H McArthur, J Force Current treatment options in oncology 22, 1-15, 2021 | 36 | 2021 |
| Nodular regenerative hyperplasia after treatment with trastuzumab emtansine J Force, R Saxena, BP Schneider, AM Storniolo, GW Sledge Jr, ... Journal of Clinical Oncology 34 (3), e9-e12, 2016 | 31 | 2016 |
| APOBEC mutagenesis inhibits breast cancer growth through induction of T cell–mediated antitumor immune responses AV DiMarco, X Qin, BJ McKinney, NMG Garcia, SC Van Alsten, ... Cancer immunology research 10 (1), 70-86, 2022 | 29 | 2022 |
| Novel cancer therapies and their association with diabetes AI Shariff, S Syed, RA Shelby, J Force, JM Clarke, D D’Alessio, L Corsino Journal of molecular endocrinology 62 (2), R187-R199, 2019 | 29 | 2019 |
| Early stage HER2-positive breast cancers not achieving a pCR from neoadjuvant trastuzumab-or pertuzumab-based regimens have an immunosuppressive phenotype J Force, LJ Howie, SE Abbott, R Bentley, PK Marcom, G Kimmick, ... Clinical breast cancer 18 (5), 410-417, 2018 | 28 | 2018 |
| Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients OM Fayanju, Y Ren, RA Greenup, JK Plichta, LH Rosenberger, J Force, ... Breast cancer research and treatment 180, 207-217, 2020 | 21 | 2020 |
| Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer J Force, A Rajan, E Dombi, SM Steinberg, G Giaccone Journal of Thoracic Oncology 6 (7), 1267-1273, 2011 | 21 | 2011 |
